Cytek Biosciences, Inc. / Fundamentals
Income statement
- Net revenue
€169.19M - Cost of goods sold
€77.12M - Gross profit
€92.07M - SG&A expenses
€82.32M - R&D expenses
€32.93M - EBITDA
-€13.29M - D&A
€4.79M - EBIT
-€23.18M - Interest expenses
-€505.74K - EBT
-€6.53M - Tax expenses
-€1.00M - Net income
-€5.52M
Cash flow statement
- Net deferred tax
-€2.06M - Non-cash items
-€1.34M - Changes in working capital
-€13.34M - Operating cash flow
€13.12M - Capex
€3.57M - Other investing cash flow
€56.96K - Net investing cash flow
-€74.40M - Total cash dividends paid
€0.00 - Issuance of common stock
€88.89K - Debt repayment
€2.17M - Other financing cash flow
-€11.69M - Net financing cash flow
-€25.78M - Foreign exchange effects
-€1.36M - Net change in cash
-€88.42M - Cash at end of period
€65.13M - Free cash flow
€16.69M
Balance sheet
- Cash and cash equivalents
€65.13M - Cash and short-term investments
€226.13M - Total receivables
€48.53M - Inventory
€42.71M - Other current assets
€13.02M - Total current assets
€330.39M - Property, plant & equipment
€29.98M - Goodwill
€14.42M - Intangible assets
€16.05M - Long-term investments
€0.00 - Other non-current assets
€4.04M - Total non-current assets
€95.36M - Total assets
€425.75M - Accounts payable
€5.91M - Short-term debt
€0.00 - Other current liabilities
€33.04M - Total current liabilities
€63.23M - Long-term debt
€12.19M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€24.49M - Total non-current liabilities
€36.67M - Total liabilities
€99.91M - Common stock
€109.61K - Retained earnings
-€45.04M - Other equity
-€32.80K - Total equity
€325.85M - Total liabilities and shareholders' equity
€425.75M
Company information
- Market capitalization
€383.52M - Employees
663 - Enterprise Value
€338.99M
Company ratios
- Gross margin
-
54.4% Much better than peer group: -116,335.3% - EBITDA margin
-
-7.9% Much better than peer group: -4,534.8% - EBIT margin
-
-13.7% Much better than peer group: -4,565.2% - EBT margin
-
-3.9% Much better than peer group: -4,788.3% - Net margin
-
-3.3% Much better than peer group: -4,562.1% - ROE
-
-1.7% Much worse than peer group: 21.0% - ROA
-
-1.3% Better than peer group: -13.1% - Asset turnover
-
39.7% Much worse than peer group: 82.7% - FCF margin
-
5.6% Much better than peer group: -3,498.7% - FCF yield
2.5% - Efficiency ratio
107.9% - Net sales per employee
-
€255.18K - Net income per employee
-
-€8.33K